阿維A市場 - 按產品類型（品牌、學名藥）、劑量強度（10毫克、25毫克、50毫克）、應用（牛皮癬、魚鱗病、毛囊病）、配銷通路（醫院藥房、零售藥房）、最終用途- 全球預測（2024 - 2032）

Acitretin Market - By Product Type (Branded, Generics), Dosage Strength (10 mg, 25 mg, 50 mg), Application (Psoriasis, Ichthyosis, Darier Disease), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), End-use - Global Forecast (2024 - 2032)

出版日期: 2024年04月26日 | 出版商:

Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在蓬勃發展的製藥和醫療保健基礎設施的支持下，全球阿維A市場2024年至2032年的複合年成長率將超過4.6%。據投資印度報告稱，印度製藥業到2024年將達到650億美元，到2030年將加倍，達到1300億美元。和卡介苗疫苗需求，以及90%的需求。阿維A在治療嚴重乾癬方面的臨床有效性和安全性已得到證實，因此在臨床實踐中已廣泛採用。

醫療保健提供者更喜歡能夠提供可靠結果且副作用最小的治療方法，因此阿維A成為首選。它在控制牛皮癬症狀（如鱗屑、發炎和斑塊形成）方面的功效可提高患者的滿意度和依從性。此外，藥物的安全性支持長期使用，進一步增強了其對臨床醫生的吸引力。

整個阿維A產業根據產品類型、劑量強度、應用、配銷通路、最終用途和地區進行分類。

學名藥領域將在預測期內實現顯著的複合年成長率。阿維A的學名藥為品牌藥物提供了具有成本效益的替代品，使更廣泛的患者群體更容易獲得治療。此外，隨著專利到期和通用替代品的出現，醫療保健系統和保險公司通常會優先考慮具有成本效益的選擇，從而激增需求。此外，阿維A的既定功效和安全性鼓勵尋求可靠治療牛皮癬及相關疾病的醫療保健提供者採用它。

到 2032 年，魚鱗病細分市場將獲得顯著的市場佔有率，因為阿維A在治療這種以乾燥、鱗狀皮膚為特徵的罕見遺傳性皮膚病方面已被證明有效。藥物能夠解決魚鱗病的根本原因，加上其相對稀有性，使阿維A成為一種有價值的治療選擇，特別是在皮膚科護理的這一專業領域中推動了其需求。

到 2032 年，北美阿維A市場將佔據重要的收入佔有率，原因是牛皮癬和相關皮膚病的流行，促使對有效治療的強勁需求。醫療保健基礎設施的進步和對皮膚科 RampD 的高度重視有助於提高治療的認知和可近性。此外，患者權益團體和醫療保健提供者努力促進慢性皮膚病的有效管理策略，推動了阿維A在北美的採用，反映出其在皮膚病護理中日益重要的地位。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Amneal Pharmaceuticals, Inc.
Biophore.
Chongqing Huapont Pharmaceutical Co., Ltd.
Globe International Limited
GSK Plc
Merck KGaA
Prasco Laboratories
SGPharma Pvt Ltd
Sionc Pharmaceuticals Pvt. Ltd.
Sun Pharma Industries Limited

簡介目錄

Product Code: 9236

Global Acitretin Market will indicate over 4.6% CAGR between 2024 and 2032, backed by booming pharmaceutical and healthcare infrastructure. According to Invest India reports, the pharmaceutical industry of India will hit USD 65 billion by 2024 and double to USD 130 billion by 2030. It supplies 60% of global vaccine production, meeting 70% of WHOs DPT and BCG vaccine demand, and 90% of measles vaccine demand. Acitretins adoption in clinical practice is catapulted by its proven clinical effectiveness and established safety profile in managing severe psoriasis.

Healthcare providers prefer treatments that offer reliable outcomes with minimal adverse effects, making acitretin a preferred choice. Its efficacy in controlling psoriasis symptoms like scaling, inflammation, and plaque formation enhances patient satisfaction and compliance. Moreover, the drugs safety profile supports long-term use, further bolstering its appeal among clinicians.

The overall acitretin industry is sorted based on product type, dosage strength, application, distribution channel, end-use, and region.

The generics segment will imply a notable CAGR during the forecast period. Generic versions of Acitretin offer cost-effective alternatives to branded medications, making treatment more accessible to a broader patient population. Additionally, as patents expire and generic alternatives become available, healthcare systems and insurers often prioritize cost-efficient options, catapulting demand. Moreover, the established efficacy and safety profile of acitretin encourages its adoption among healthcare providers seeking reliable treatments for psoriasis and related conditions.

The ichthyosis segment will procure a noticeable market share by 2032, because of the proven efficacy of acitretin in managing this rare genetic skin disorder characterized by dry, scaly skin. The medications ability to address the underlying causes of ichthyosis, coupled with its relative rarity, positions acitretin as a valuable therapeutic option, driving its demand specifically within this specialized segment of dermatological care.

North America acitretin market will hold a significant revenue share by 2032, attribute to the prevalence of psoriasis and related skin disorders, prompting a robust demand for effective treatments. Advancements in healthcare infrastructure and a strong emphasis on dermatological R&D contribute to increased awareness and accessibility of treatments. Moreover, patient advocacy groups and healthcare providers efforts to promote effective management strategies for chronic skin conditions usher the adoption of acitretin in North America, reflecting its growing importance in dermatological care.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.2 Rising prevalence of psoriasis
- 3.2.3 Advancements in treatment
- 3.2.4 Growing awareness and diagnosis
- 3.2.5 Industry pitfalls & challenges
- 3.2.6 Stringent regulatory requirements
- 3.2.7 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Branded
5.3 Generics

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2. 10mg
6.3. 25mg
6.4. 50mg

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Psoriasis
7.3 Ichthyosis
7.4 Darier disease
7.5 Pityriasis rubra pilaris
7.6 Solid organ transplants
7.7 Grover's disease
7.8 Lichen planus
7.9 Lupus erythematosus

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa